2013
DOI: 10.1378/chest.12-1639
|View full text |Cite
|
Sign up to set email alerts
|

Cystic Fibrosis Therapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
41
0
2

Year Published

2013
2013
2023
2023

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 78 publications
(43 citation statements)
references
References 44 publications
0
41
0
2
Order By: Relevance
“…It was also found that sharp debridement followed by antibiotic treatment is very promising for healing the wounds (Dowd et al, 2011). In the treatment of CF, antibiotics combination therapies, for example, fosfomycin and tobramycin, are recommended (Hoffman and Ramsey, 2013). It was also shown that mannitol enhances antibiotic susceptibility of the persister bacteria in P. aeruginosa biofilms (Barraud et al, 2013).…”
Section: Pseudomonas Aeruginosa Biofilmsmentioning
confidence: 99%
“…It was also found that sharp debridement followed by antibiotic treatment is very promising for healing the wounds (Dowd et al, 2011). In the treatment of CF, antibiotics combination therapies, for example, fosfomycin and tobramycin, are recommended (Hoffman and Ramsey, 2013). It was also shown that mannitol enhances antibiotic susceptibility of the persister bacteria in P. aeruginosa biofilms (Barraud et al, 2013).…”
Section: Pseudomonas Aeruginosa Biofilmsmentioning
confidence: 99%
“…61 Currently active trials of gene therapy are going on over such varied diseases cystic fibrosis, vein graft rejection, psychiatric d i sorders, inner ear developmental anomalies, brain tumors, mitochondrial genetic diseases. [61][62][63][64][65][66][67][68][69] The use of viruses to deliver genes has shown risks to human health, making trials with these viruses controversial. Another method involves the use of liposomes, hollow membranous spheres which encapsulate the gene.…”
Section: Transgenic Animalsmentioning
confidence: 99%
“…An orally active medication, Ivacaftor has been approved, initially for use in patients with the G551D mutation, and latterly for the other Class III gating mutations. There are now several reports on mutation specific treatment for CF [2]. In this issue of IJP, Guglani has reviewed all ongoing studies on advances in treatment of CF [3].…”
mentioning
confidence: 99%